BDR Pharmaceutical on Tuesday announced that it has launched the first generic Apalutamide (Brand name APATIDE) in India to treat metastatic castration-sensitive Prostrate cancer and non-metastatic castration-resistant Prostrate cancer.
According to the company, the product will be available across India and shall be of 60 mg strength and available in two packs – 60 tabs and 120 tabs.
Raheel Shah, Director Business Development, BDR Group told Financial Express.com that the price of the generic drug is one-third the price of the innovator brand. The price for a bottle of 60 tablets is Rs 22,500 and for a bottle of 120 tablets is Rs 45,000.
Apalutamide in combination with anti-androgen therapy will significantly improve chances for survival within Metastatic Castration Sensitive Prostrate Cancer patients, the company claims.
“The first generic drug Apalutamide for the treatment of prostate cancer is affordable and has reduced the cost by one-third compared to the previous product. Apalutamide will significantly improve overall survival (OS) and radiographic progression-free survival with in patients.The medication reduces the risk of disease progression or death by 71% and increases life expectancy by 2 years,” Shah told Financial Express.com.
The prostate cancer’s burden is expected to grow to 1.7 million new cases and 4,99,000 new deaths by 2030 simply due to the growth and aging of the global population. In India, Prostate cancer is the second most common cause of cancer and the sixth leading cause of cancer deaths among men.
On what more the company is planning in this segment, Shah told Financial Express.com: “We are in the discussion stage right now and can’t disclose more details as of now.”
The company claims that Apalutamide will play a role in significantly improving overall survival (OS) and radiographic progression-free survival in patients.
The company also informed that the outcome of the study indicates that the drug can contribute to the overall health-related quality of life with its addition to androgen-deprivation therapy.
“Early identification of newer molecules for life-threatening diseases encourages us to advance the development and introduction of products through the strength of backward integration of developing & manufacturing APIs to facilitate humankind. This type of advanced molecule in the treatment of various cancer indications is testimony towards our commitment to providing access to affordable medicines without compromising patients’ safety as well as qualitative standards. At BDR, our goal is to support the vision of the Honourable Prime Minister on being Atmanirbhar Bharat and make affordable and quality medicines accessible for the people of India,” Raheel Shah, Director Business Development, BDR Group said in a statement on Tuesday.
BDR Pharmaceuticals, a key player in the manufacturing of Indian Cancer medicines, has contributed to the treatment of Prostate Cancer starting with Abiraterone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
The group focuses on development in four specialized therapeutic segments – Oncology, Critical Care, Gynecology and Neurology.